Anti-Mullerian Hormone, a Measure of Ovarian Reserve, Is Low in Female Subjects in the Multi-Center Study of Hydroxyurea

Introduction: Whether sickle cell disease (SCD) or its primary treatment, hydroxyurea (HU), limits reproductive potential in affected women is unknown. Females are born with a finite number of eggs. Anti-Mullerian Hormone (AMH), produced by immature ovarian follicles, is an established method to measure ovarian reserve. Two studies of AMH, one in adolescents with SCD and another in adult women with SCD exist, but neither normal AMH values nor the effect of HU on AMH are established in girls and women with SCD. The purpose of this study is to evaluate AMH levels in women who participated in the seminal study that led to FDA-approval for HU in adults with SCD, the Multi-Center Study of Hydroxyurea (MSH). Methods: The MSH was a randomized placebo-controlled trial (RCT) of HU. The RCT demonstrated HU's efficacy, so a 10-year MSH extension study was conducted to assess HU's potential for “mutagenesis, teratogenesis and oncogenesis”. Although no samples from the RCT remain, serum samples (n=285) were available for many women in the follow-up study (n=93). We measured AMH in these samples using the CLIA-certified electrochemiluminescence assay in clinical use at our institution (Esoterix Labs, Calabasas Hills, CA). The assay's reference median AMH in women ages 26 - 30 years is 4.20 ng/mL, and in women 36 - 40 years is 1.69 ng/mL. The assay's lower limit of detection is 0.015ng/mL. Samples with AMH levels beneath the detection limit were run in duplicate when sufficient sample existed; this did not change any results. Here, we report AMH levels in female subjects (n=57) with a serum sample from the first annual follow-up visit (AV01). Descriptive statistics with median values reported for non-parametric variables (Mann Whitney U Test) were performed. AMH /= 1 ng/ml) and low ( Results: Samples from the first post-study visit were available for 57 women; the median time to first post-study visit was 31 months (IQR 6.5) after RCT closure. Median values for the cohort were: AMH, 0.306ng/ml (IQR 1.162), age, 32.50 years (IQR 11), MCV, 102.0 fl (IQR 15.8), and HU exposure, 23.92 months (IQR 30.72). Figure 1 shows AMH distribution in the cohort. AMH levels were low in 77% (44 of 57) of the cohort. Table 1 compares patient characteristics of subjects with low AMH (n=44) versus normal AMH (n=13). In univariate analysis, subjects with low AMH were older (34.5 vs 24.5, p Conclusions: Most women (77%) in this cohort had low AMH, associated with older age and higher MCV. This preliminary analysis raises concerns about diminished ovarian reserve in women with SCD. Although months of HU exposure was not associated with low AMH, HU exposure does not account for adherence, which is a major limitation in most sickle cell studies. MCV which increases with consistent HU use and is a biological proxy measure of the last 3-months of HU adherence, was associated with low AMH. Ovarian reserve was not a planned endpoint in the MSH. A prospective study of ovarian reserve in women with SCD is needed to understand how the physiology of SCD itself or exposure to HU may influence multiple fertility endpoints. Download : Download high-res image (102KB) Download : Download full-size image Disclosures Chaturvedi: Shire/Takeda: Research Funding; Sanofi: Consultancy; Alexion: Consultancy. Lanzkron: PCORI: Research Funding; NIH: Research Funding; Pfizer: Research Funding; Global Blood Therapeutics: Research Funding; Ironwood: Research Funding; HRSA: Research Funding.